Abbott introduces the Afinion™ 2 analyzer rapid test system for diabetes management

A new system developed by Abbott helps people with diabetes get the HbA1c results they need within 3 minutes.

 

Editor's Note: This article originally appeared on Abbott's website.

ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

The Afinion 2 analyzer is a compact rapid, multi-assay platform that streamlines and simplifies the delivery of actionable, accurate measurements of hemoglobin A1c (HbA1c) and albumin to creatinine ratio (ACR) results at the point of care. The system arms healthcare professionals with the information needed to make fast and accurate medical decisions—three minutes for HbA1c and five minutes for ACR—enabling healthcare professionals to dedicate more time to counseling patients within a single office visit. Click here to continue >>

 

News from our partners

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers